How Much Does Peptide Therapy Cost? A Transparent Breakdown

Budget $250–$700 for your first month all-in. This typically covers an initial consultation (free at Peptide Hub), a lab panel ($150–$300), and your first month’s compound ($100–$300 for a standard GH-peptide protocol). Subsequent months drop significantly once labs are established — most patients settle into $100–$400/month depending on protocol complexity. Total first-year cost across peptides, labs, and consultations generally runs $2,000–$2,800.

Yes. Always confirm whether the quoted monthly price includes the provider supervision fee, syringes, supplies, and shipping — or whether those are billed separately. Some telehealth platforms charge a $50–$100/month platform membership on top of the compound cost. Ask for an itemized estimate before you commit. At Peptide Hub, pricing is fully disclosed before any financial commitment.

Rarely, and only for FDA-approved peptides used for their approved indications — for example, semaglutide (Ozempic) for type 2 diabetes, Wegovy for weight management meeting BMI criteria, or Vyleesi for HSDD. Compounded peptides like Sermorelin, CJC-1295, BPC-157, and Thymosin Alpha-1 are 100% self-pay regardless of medical indication. Medicare does not cover compounded medications, and even branded GLP-1s face restrictions under Medicare for weight loss use.

Yes, in most cases you can. Both Health Savings Accounts and Flexible Spending Accounts cover prescribed peptide protocols as a qualified medical expense, provided the therapy is prescribed by a licensed physician for a documented medical condition. Ask your provider for a letter of medical necessity before submitting for reimbursement, as documentation is typically required in the event of an audit. The tax savings this creates are meaningful: depending on your bracket, HSA and FSA funds effectively reduce your real cost by 22 to 37 percent. For 2026, the IRS set HSA contribution limits at $4,400 for self-only coverage and $8,750 for family coverage under Revenue Procedure 2025-19, which is enough to fund a full year of most standard protocols.

The situation is actively being resolved as of this writing. Both compounds were placed on the FDA’s Category 2 restricted list in 2023, which prevented licensed compounding pharmacies from preparing them for patients. In February 2026, HHS Secretary RFK Jr. announced that approximately 14 of the 19 previously restricted peptides are expected to return to legal compounding status. This group includes BPC-157, TB-500, CJC-1295, Ipamorelin, and Thymosin Alpha-1. The FDA’s Pharmacy Compounding Advisory Committee is formally reviewing BPC-157 and TB-500 at its meeting on July 23 and 24, 2026. It is important to understand that removal from Category 2 is not the same as FDA approval. A valid physician prescription and a licensed compounding pharmacy are still required. Confirm the current compounding status of these compounds with your provider before initiating any protocol that includes them.

Tesamorelin, sold under the brand name Egrifta WR, is an FDA-approved biologic drug rather than a compounded peptide. It must be manufactured to full pharmaceutical drug standards, which drives significantly higher production costs compared to compounded alternatives. Tesamorelin also holds a unique position in the clinical evidence base: it is the only peptide with evidence strong enough to earn FDA approval for visceral fat reduction, supported by two Phase 3 randomized controlled trials involving 816 patients. When prescribed off-label for general metabolic health rather than for its approved HIV lipodystrophy indication, insurance rarely covers it. Patients typically bear the full cost of $400 to $800 per month. Sermorelin, by contrast, is compounded and priced competitively at $100 to $300 per month.

Most providers structure an initial protocol of three to six months, after which labs and clinical response are reassessed together. GH-stimulating peptides generally require at least eight to twelve weeks before meaningful and measurable results appear. Protocols shorter than this timeframe rarely justify the investment. Following the initial cycle, some patients choose annual protocols to maintain progress, while others transition to long-term maintenance for ongoing hormone optimization. The duration of your protocol is one of the most significant factors in your total annual cost, and any legitimate provider should offer you a realistic projection upfront before you begin.

At Peptide Hub, the 15-minute consultation is a genuine clinical intake conducted by a licensed specialist. Its purpose is to determine whether peptide therapy is appropriate for your specific situation and which protocol makes the most clinical sense for your goals and health history. No financial commitment is required before or after the call. If peptide therapy is not the right fit for you, you will be told that directly. You can schedule your consultation at advancedpeptidetherapy.com/contact-us.

A standard pre-therapy hormone panel typically includes IGF-1 as a proxy for GH status, total and free testosterone, a complete blood count, a comprehensive metabolic panel, a full thyroid panel covering TSH, free T3 and free T4, and a lipid panel. Depending on your goals and health history, your provider may also order estradiol, DHEA-S, cortisol, or fasting insulin. At most major reference labs, a comprehensive panel of this scope costs between $150 and $400 out of pocket. Some providers include a baseline panel in the first-month program cost, while others bill it separately. Clarifying this in advance prevents surprises on your first invoice.

The difference is substantial. Branded Wegovy carries a retail list price of approximately $1,350 per month. Manufacturer direct-pay programs have closed part of that gap: LillyDirect offers Zepbound (tirzepatide) at $349 to $549 per month depending on dose, and Novo Nordisk runs a comparable self-pay program for Wegovy. Compounded semaglutide through telehealth platforms runs $150 to $500 per month. However, the compounding landscape for GLP-1 medications is actively regulated and changes as shortage status is updated by the FDA. Availability of compounded semaglutide is not guaranteed at any given time. Always verify current compounding authorization with a licensed provider before purchasing, and factor in the possibility that branded direct-pay pricing may be competitive enough to make compounding unnecessary for your situation.